Champions Oncology's gross profit for the
three
months ended in Jan. 2024 was $4.17 Mil. Champions Oncology's gross profit for the trailing twelve months (TTM) ended in Jan. 2024 was $19.74 Mil.
Champions Oncology had a gross margin of 34.70% for the quarter that ended in Jan. 2024 => Competition eroding margins
During the past 13 years, the highestGross Margin % of Champions Oncology was 51.88%. The lowest was 13.88%. And the median was 46.43%.
Champions Oncology Gross Profit Historical Data
The historical data trend for Champions Oncology's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Champions Oncology's Gross Profit
For the Biotechnology subindustry, Champions Oncology's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Gross Profit distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Gross Profit falls into.
Champions Oncology Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Champions Oncology's Gross Profit for the fiscal year that ended in Apr. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.74 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Champions Oncology (NAS:CSBR) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Champions Oncology had a gross margin of 34.70% for the quarter that ended in Jan. 2024 => Competition eroding margins
Champions Oncology Gross Profit Related Terms
Thank you for viewing the detailed overview of Champions Oncology's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Champions Oncology (Champions Oncology) Business Description
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSBR has been successfully added to your 